<DOC>
	<DOC>NCT02301624</DOC>
	<brief_summary>To evaluate the safety and efficacy of eculizumab in the treatment of refractory gMG as an extension trial for the subjects who have participated in the ECU-MG-301 trial.</brief_summary>
	<brief_title>ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis</brief_title>
	<detailed_description>Trial ECU-MG-301, a phase III clinical trial, has been initiated to evaluate the safety and efficacy of eculizumab in the treatment of refractory gMG. This extension trial is designed to provide the subjects who have participated in the ECU-MG-301 trial an opportunity to receive eculizumab and to collect clinical data that will provide long term safety and efficacy information on eculizumab in subjects with refractory gMG.</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>1. Subject has completed the ECUMG301 trial. 2. Subject has given written informed consent. 3. Subject is willing and able to comply with the protocol requirements for the duration of the trial. 4. Female subjects of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG]). All subjects must practice an effective, reliable and medically approved contraceptive regimen during the trial and for up to 5 months following discontinuation of treatment. 1. Subjects who withdrew from the ECUMG301 trial as a result of an AE related to trial drug. 2. Female subjects who are pregnant, breastfeeding or intend to conceive during the course of the trial. 3. Any medical condition or circumstances that, in the opinion of the Investigator, might interfere with the subject's participation in the trial, pose any added risk for the subject, or confound the assessment of the subjects.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>gMG</keyword>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>